Skip to content
Search for...
Lyhyesti suomeksi
Contact Us
Home
Investors
Why Invest?
Reports and presentations
Corporate Governance
Articles of Association
General Meetings
Board of Directors
Management
Auditor
Press Releases
Investor Relations
Technology
Traumatic Brain Injury
Biomarker R&D program
Proof of concept
Second clinical trial
Third clinical trial
Assay development plan
Drug development program
IP Rights
Company Profile
Letter From Our CEO
Business Strategy
Board of Directors
Management
Team
News & Events
Press Releases
Lehdistötiedotteet
Articles
Videos
Search for...
Contact Us
Lyhyesti suomeksi
Navigation Menu
Navigation Menu
Home
Investors
Why Invest?
Reports and presentations
Corporate Governance
Articles of Association
General Meetings
Board of Directors
Management
Auditor
Press Releases
Investor Relations
Technology
Traumatic Brain Injury
Biomarker R&D program
Proof of concept
Second clinical trial
Third clinical trial
Assay development plan
Drug development program
IP Rights
Company Profile
Letter From Our CEO
Business Strategy
Board of Directors
Management
Team
News & Events
Press Releases
Lehdistötiedotteet
Articles
Videos
Uncategorized
Medicortex’s Share Issue continues
23.8.2024
27.8.2024
Medicortex plans to get listed: Share Issue 5.-20.8.24
5.8.2024
23.8.2024
Medicortex signed a $1.4 M research grant contract with the U.S. DoD
24.6.2024
23.8.2024
Medicortex appoints new members for Board of Directors
3.5.2024
23.8.2024
Reminder to register attendance for AGM
12.4.2024
23.8.2024
Varsinainen yhtiökokous
25.3.2024
23.8.2024
Annual General Meeting
25.3.2024
23.8.2024
Vielä vähän aikaa kerätä Business Finland-päätöksen alkupääoma!
21.3.2024
23.8.2024
Medicortex saa jatkoaikaa Business Finlandin rahoituspäätökselle
27.2.2024
23.8.2024
Medicortex receives extension to Business Finland funding decision
27.2.2024
23.8.2024
1
2
Seuraava »